{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-008670","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.062255+00:00","generated_at":"2026-06-05T05:01:31.828627+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial","bullets":["Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.","Independent Safety Review Committee recommended continuing to multiple doses of Decoy20.","Company has started screening patients for multi-dose safety and efficacy across multiple cancer types.","Animal models demonstrated Decoy20 safety in several multiple-dose schedules."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-008670","json":"https://secwatch.observer/filing/0001493152-24-008670.json","markdown":"https://secwatch.observer/filing/0001493152-24-008670.md","text":"https://secwatch.observer/filing/0001493152-24-008670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/0001493152-24-008670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:01:31.828627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}